Noa Therapeutics
Serena Mandla, P.Eng, MASc. is a professional with a background in biomaterials and biomedical engineering. They have experience working in various research and engineering roles at prestigious institutions and companies such as Quthero, Inc., University of Toronto, and Harvard Medical School. Currently serving as the CSO at Noa Therapeutics, Serena's work focuses on the complexity of diseases and developing innovative solutions for wound healing and tissue regeneration. Their extensive experience in research, program management, and teaching showcases a dedication to advancing the field of biotechnology.
This person is not in any teams
Noa Therapeutics
Noa Therapeutics Inc. (Noa) is a preclinical Canadian biotech company aiming to defy the convention of traditional drug development to revolutionize treatment options for those living with complex inflammatory skin diseases. Leveraging intelligent design, Noa is pioneering the development of multimodal therapeutics; a singularly radical approach to address unmet needs and unlock opportunities within underserved and untapped markets. Targeting a first use case in atopic dermatitis, Noa’s non-steroidal small molecules aim to simultaneously addressing three constructive therapeutic targets. Through this multilateral approach, Noa strives to provide meaningful outcomes and establish a new, inclusive, standard for the first-line-treatment of inflammatory skin disease.